Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers

International Journal of Gynecological Cancer

Volumn 22, Issue 8, 2012, Pages 1367-1372

  Cote, Michele L ^a   Atikukke, Govindaraja ^a   Ruterbusch, Julie J ^a   Olson, Sara H ^a   Sealy Jefferson, Shawnita ^a   Rybicki, Benjamin A ^a   Alford, Sharon Hensley ^a,b   Elshaikh, Mohammad A ^d   Gaba, Arthur R ^a   Schultz, Daniel ^c   Haddad, Ramsi ^a,b   Munkarah, Adnan R ^e   Ali Fehmi, Rouba ^f  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^e HENRY FORD HEALTH SYSTEM   (United States)

^f Results Genomics   (Canada)

Author keywords

Endometrial cancer; Oncogene mutation; Race

Indexed keywords

K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC SUBUNIT P110 ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL HYSTERECTOMY; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER SURGERY; CANCER TISSUE; CLEAR CELL CARCINOMA; COLLOID CARCINOMA; EARLY CANCER; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; EUROPEAN AMERICAN; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MIXED MULLERIAN TUMOR; MIXED TUMOR; MUTATIONAL ANALYSIS; ONCOGENE; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84867246694     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31826b1110     Document Type: Article

References (23)

1. Howlader N, Krapcho M, Neyman N, et al. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011.
2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10-17.
3. Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol. 1997;81:228-232.
4. Maxwell GL, Tian C, Risinger J, et al. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer. 2006;107:2197-2205.
5. Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer. 2003;98:176-186.
6. Bach PB, Schrag D, Brawley OW, et al. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002;287:2106-2113.
7. Farley JH, Tian C, Rose GS, et al. Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study. Cancer. 2010;116:355-361.
8. Madison T, James SA, Schwartz AG, et al. Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival. Am J Public Health. 2004;94:2104-2111.
9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
10. Pearce MEM. Somatic mutation analysis in tumor samples using the Sequenom MassARRAY System. Nat Methods. 2009;6:vii-viii.
11. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655-1657.
12. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.
13. Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A. 2007;104:5569-5574.
14. Rudd ML, Price JC, Fogoros S, et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res. 2011;17:1331-1340.
15. Janku F, Tsimberidou AM, Garrido-Laguna I, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011;10: 558-565.
16. Hayes MP, Douglas W, Ellenson LH. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol. 2009;113:370-373.
17. Konstantinova D, Dimitrov R, Savov A, et al. Rare mutations in the PIK3CA gene contribute to aggressive endometrial cancer. DNA Cell Biology. 2010;29:65-70.
18. Catasus L, Gallardo A, Cuatrecasas M, et al. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol. 2008;21:131-139.
19. Alexander-Sefre F, Salvesen HB, Ryan A, et al. Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis. Gynecol Oncol. 2003;91:218-225.
20. Caduff RF, Johnston CM, Frank TS. Mutations of the Ki-ras oncogene in carcinoma of the endometrium. Am J Pathol. 1995;146:182-188.
21. Ito K, Watanabe K, Nasim S, et al. K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient. Gynecol Oncol. 1996;63:238-246.
22. Mizuuchi H, Nasim S, Kudo R, et al. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Res. 1992;52:2777-2781.
23. Sasaki H, Nishii H, Takahashi H, et al. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res. 1993;53:1906-1910.